Efficacy and safety of a new leuprolide acetate [leuprorelin] 3.75 mg depot formulation, GP-Pharm S.A., when given as palliative treatment to prostate cancer patients
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Leuprorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GP Pharm
- 13 Nov 2007 Status changed from in progress to completed.
- 22 Oct 2005 New trial record.